Dr Merseburger on Real-World Outcomes With First-Line Axitinib Plus Avelumab in RCC
Dr Gupta on Updated Data With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer
Ide-Cel Boosts Response in Myeloma With < CR After Upfront Auto-HCT and Lenalidomide Maintenance
Non-Myeloablative HSCT Regimen Shows Potential for Immune Tolerance in Haploidentical Living Donor Combined Kidney/Hematopoietic Transplant